Chronic lymphocytic leukaemia: open trials in Czechia

19 open trials have a site in Czechia. Registry data; only the trial team decides who can take part.

NCT06588478
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Trial Treatment · Phase 2 · Loxo Oncology, Inc.
Fakultni nemocnice Brno, Brno · Fakultni Nemocnice Hradec Kralove, Novy Hradec Kralove · Vseobecna fakultni nemocnice v Praze, Prague · Fakultni nemocnice Kralovske Vinohrady, Prague
Registry updated 2026-11-04
NCT07218341
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Trial Treatment · Phase 4 · Eli Lilly and Company
Fakultni nemocnice Hradec Kralove, Hradec Králové
Registry updated 2026-11-04
2023-510147-37-00
Acalabrutinib Monotherapy vs Investigator’s Choice of Treatment in Patients with Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairment
Trial Treatment · Phase 4 · AstraZeneca AB
Fakultni nemocnice Brno, Brno · Fakultni Nemocnice Hradec Kralove, Novy Hradec Kralove · Fakultni nemocnice Kralovske Vinohrady, Prague
Registry updated 2026-10-28
NCT06564038
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Trial Treatment · Phase 1/2 · AstraZeneca
Fakultni nemocnice Ostrava, Ostrava · Institute of Hematology and Blood Transfusion, Prague · Vseobecna fakultni nemocnice v Praze, Prague
Registry updated 2026-10-28
NCT04728893
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Trial Treatment · Phase 2 · Merck Sharp & Dohme LLC
Fakultní nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika (Site 0600), Brno · Fakultni nemocnice Hradec Kralove (Site 0601), Hradec Králové
Registry updated 2026-10-27
NCT06943872
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Trial Treatment · Phase 3 · BeOne Medicines
Fakultni nemocnice Brno, Brno · Fakultni nemocnice Hradec Kralove, Hradec Králové · Institute of Hematology and Blood Transfusion, Prague · Vseobecna fakultni nemocnice v Praze, Prague
Registry updated 2026-10-23
NCT07024706
MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab
Trial Treatment · Phase 2 · AstraZeneca
Fakultni nemocnice Brno, Brno · Fakultni nemocnice Hradec Kralove, Hradec Králové · Fakultni nemocnice Ostrava, Ostrava
Registry updated 2026-10-23
NCT07648264
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Trial Treatment · Phase 3 · CSL Behring
FH Hradec Kralove, Hradec Králové · FH Ostrova, Ostrova · Fakultni nemocnice Kralovske Vinohrady, Prague · UHKT Praha, Prague
Registry updated 2026-10-14
NCT06136559
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Fakultni Nemocnice Hradec Kralove, Novy Hradec Kralove · University Hospital Olomouc, Olomouc · Vseobecna Fakultni Nemocnice V Praze, Prague 2
Registry updated 2026-10-13
2023-510294-34-00
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
Trial Treatment · Phase 3 · University Of Cologne
Fakultni nemocnice Brno, Brno · Fakultni Nemocnice Hradec Kralove, Novy Hradec Kralove · University Hospital Olomouc, Olomouc · Fakultni Nemocnice Plzen, Plzen 23 · Fakultni nemocnice Kralovske Vinohrady, Prague · Vseobecna fakultni nemocnice v Praze, Prague
Registry updated 2026-10-01
NCT07582432
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Trial Treatment · Phase 3 · Grifols Biologicals, LLC
Fakultni nemocnice Ostrava, Ostrava · Fakultni Nemocnice Plzen, Plzen 23 · Fakultní Nemocnice Královské Vinohrady, Praha 10
Registry updated 2026-10-01
NCT06846671
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Trial Treatment · Phase 3 · BeOne Medicines
Fakultni nemocnice Brno, Brno · Fakultni nemocnice Hradec Kralove, Hradec Králové · Fakultni nemocnice Ostrava, Ostrava · Vseobecna fakultni nemocnice v Praze, Prague
Registry updated 2026-09-28
NCT07277231
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Trial Treatment · Phase 3 · BeOne Medicines
Fakultni nemocnice Brno, Brno · Fakultni nemocnice Hradec Kralove, Hradec Králové · University Hospital Olomouc, Olomouc · Fakultni nemocnice Ostrava, Ostrava · Fakultni Nemocnice Plzen, Plzen 23 · Vseobecna fakultni nemocnice v Praze, Prague
Registry updated 2026-09-28
NCT06651970
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
Trial Treatment · Phase 4 · AstraZeneca
Brno · Hradec Králové · Prague
Registry updated 2026-09-24
NCT05254743
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Trial Treatment · Phase 3 · Loxo Oncology, Inc.
Fakultni nemocnice Brno, Brno · Fakultni Nemocnice Hradec Kralove, Novy Hradec Kralove · Fakultni nemocnice Ostrava, Ostrava · Fakultni Nemocnice Plzen, Plzen 23 · Vseobecna fakultni nemocnice v Praze, Prague · Fakultní Nemocnice Královské Vinohrady, Prague 10
Registry updated 2026-08-17
NCT07342478
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Trial Treatment · Phase 3 · Newave Pharmaceutical Inc
Fakultni nemocnice Brno, Brno · University Hospital Olomouc, Olomouc · Fakultni nemocnice Ostrava, Ostrava · Fakultni nemocnice Kralovske Vinohrady, Prague
Registry updated 2026-08-11
NCT06319456
A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
Trial Treatment · Phase 3 · Ascentage Pharma Group Inc.
Fakultni nemocnice Brno, Brno
Registry updated 2026-07-28
NCT06104566
Global Trial in APG2575 for Patients With CLL/SLL
Trial Treatment · Phase 3 · Ascentage Pharma Group Inc.
Fakultni Nemocnice Hradec Kralove, Novy Hradec Kralove
Registry updated 2026-06-18
NCT04502394
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Trial Treatment · Phase 1/2 · Kartos Therapeutics, Inc.
Fakultni Nemocnice Hradec Kralove, Novy Hradec Kralove · Fakultni nemocnice Ostrava, Ostrava · Vseobecna fakultni nemocnice v Praze, Prague
Registry updated 2022-08-04

All Chronic lymphocytic leukaemia trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error